When was Constructive Bio founded?

Constructive Bio was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Constructive Bio located?

Constructive Bio is headquartered in Saffron Walden, United Kingdom. It is registered at 27 OLD GLOUCESTER STREET,LONDON,UNITED KINGDOM,WC1N 3AX.

Who is the current CEO of Constructive Bio?

Ola Wlodek of Constructive Bio.

Which legal entities is Constructive Bio associated with?

Constructive Bio is associated with Constructive Bio Limited and 1 other.

How many employees does Constructive Bio have?

As of Sep 30, 2026, the latest employee count at Constructive Bio is 70.

Is Constructive Bio a funded company?

Constructive Bio is a funded company, having raised a total of $75M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 15, 2022.

How much is Constructive Bio worth?

The latest valuation of Constructive Bio is £***** as of Jul 28, 2023.

When was the latest funding round of Constructive Bio?

Constructive Bio's latest funding was a $***** Series A round on Mar 27, 2025, with participation from 1 investor. Its primary sector is Genomics. In United Kingdom, the Genomics sector has seen $138M in funding in 2026 to date.

Where does Constructive Bio rank among its competitors?

Constructive Bio ranks 109th amongst 635 active competitors, of which 157 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Constructive Bio?

Constructive Bio's top competitors include Syngenta, Twist Bioscience and Beam Therapeutics. Among them, Antheia secured the most recent funding round in January, 2026.

Constructive Bio - 2026 Company Profile, Team, Funding & Competitors

Constructive Bio is a series A company based in Saffron Walden (United Kingdom), founded in 2022. It operates as a Provider of a platform for genome and polymer synthesis. Constructive Bio has raised $75M in funding from investors like Ahren, Paladin Capital and OMX Ventures, with a current valuation of £*****. The company has 635 active competitors, including 157 funded and 126 that have exited. Its top competitors include companies like Syngenta, Twist Bioscience and Beam Therapeutics.

Company Details

Provider of a platform for genome and polymer synthesis. The company pioneered the development of methods for reprogramming the genetic code of living organisms that are resistant to a wide variety of viruses, can be programmed to make synthetic, polymers, and even perform entirely new functions. It has applications across a range of industries including novel therapeutics and antibiotics enhanced agriculture, manufacturing, and materials.

Website: constructive.bio
Email ID: *****@constructivebio.com
Registered Address: 27 OLD GLOUCESTER STREET,LONDON,UNITED KINGDOM,WC1N 3AX

Key Metrics

Founded Year

2022

Location

Saffron Walden, United Kingdom

Stage

Series A

Total Funding

$75M in 3 rounds

Latest Funding Round

Series A, Mar 27, 2025, $*****

Post Money Valuation

£***** as on Jul 28, 2023

Investors

Ahren & 10 more

Ranked

109^th among 635 active competitors

Employee Count

70 as on Sep 30, 2026

Similar Companies

Syngenta & 247 more

View Constructive Bio's full profile

Constructive Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
CONSTRUCTIVE BIOLOGY LIMITED CIN: 13758641 , United Kingdom, Active	Nov 21, 2021	-	28 (As on Dec 31, 2024)
Constructive Bio Limited CIN: 13758641 , Germany, Active	Nov 21, 2021	-	3 (As on Nov 30, 2022)

Constructive Bio has raised a total funding of $75M over 3 rounds. Its first funding round was on Aug 15, 2022. Its latest funding round was a Series A round on Mar 27, 2025 for $*****. 1 investor participated in its latest round. Constructive Bio has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Constructive Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 27, 2025	6022564	Series A	4254371	6815625	2893806	7313081
Sep 24, 2024	5824413	Series A	6794150	1813960	5246533	Fine Structure Ventures & 2 more
Aug 15, 2022	3644196	Seed	7637920	3908140	Ahren	Amadeus Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Constructive Bio's funding rounds and investors

Here are the details of Constructive Bio's key team members:

Ola Wlodek: CEO of Constructive Bio.

Constructive Bio's Board of Directors

Constructive Bio's board has 7 active members. Rahul Dhanda, Paul Conley, Shyam Kamadolli, Jason William Karl Chin, Aleksandra Maria Wlodek, Gregory Paul Winter and Paul Conley are independent board members.

Here is the list of Constructive Bio's board of directors:

Name	Type	Representing	Status	Duration
Rahul Dhanda	Independent board member	-	Current	3y 6m
rtqwrgy	Independent board member	-	Current	1y 1m
kbhctdh	Independent board member	-	Current	3y 5m
rjgjbku	Independent board member	-	Current	5y 7m
bjcixjd	Independent board member	-	Current	6y 8m
fmmggyu	Independent board member	-	Current	6y 9m
npxhxil	Independent board member	-	Current	5y 9m

View details of Constructive Bio's Founder profiles and Board Members

Constructive Bio's employee count trend

Constructive Bio has 70 employees as of Sep 26. Here is Constructive Bio's employee count trend over the years:

Employee count trend for Constructive Bio

Uncover Constructive Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Constructive Bio include Syngenta, Twist Bioscience and Beam Therapeutics. Here is the list of Top 10 competitors of Constructive Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
2nd	Twist Bioscience 2013, San Francisco (United States), Public	Developer of a semiconductor-based DNA synthesis platform	$321M	Foresite Capital, Fidelity Investments & 39 others	74/100
3rd	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Cormorant-asset & 16 others	72/100
4th	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, T. Rowe Price & 53 others	70/100
5th	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	69/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	69/100
7th	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	68/100
8th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of genome editing therapeutics using CRISPR and Cas9 technology	$85M	Atlas Venture, Novartis & 10 others	68/100
9th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$293M	Baillie Gifford, ORI Capital & 30 others	67/100
10th	Synthego 2012, Redwood City (United States), Acquired	Manufacturer of custom CRISPR gene editors and molecular biology reagents	$460M	8VC, Perceptive Advisors & 30 others	67/100
109th	Constructive Bio 2022, Saffron Walden (United Kingdom), Series A	Provider of a platform for genome and polymer synthesis	$75M	ND Capital, Ahren & 9 others	44/100